T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
Phase 2
85
about 13 years
18–72
1 site in MD
What this study is about
This trial is testing a new treatment called T cell receptor immunotherapy to see if it can shrink tumors in people with advanced non-small cell lung cancer. It involves taking special immune cells from the patient's tumor, growing them in a lab, and then giving them back to the patient. This treatment may be given along with chemotherapy.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Young TIL
- 2.Take Aldesleukin
- 3.Take Cyclophosphamide
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
aldesleukin, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine
infusion
Primary: Response rate
Secondary: Frequency and severity of treatment-related adverse events
Oncology